Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 301 AL 315

Developing novel blood-based biomarkers for Alzheimer's disease

Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM.

Alzheimers Dement. 2014 Jan;10(1):109-14. doi: 10.1016/j.jalz.2013.10.007.

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N Jr, Palmblad J.

J Intern Med. 2014 Apr;275(4):428-36. doi: 10.1111/joim.12166. Epub 2014 Jan 11.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.

N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

A systematic review of biomarkers for disease progression in Alzheimer's disease

McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

PLoS One. 2014 Feb 18;9(2):e88854. doi: 10.1371/journal.pone.0088854. eCollection 2014.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191.

Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications

Bagnoli S, Piaceri I, Sorbi S, Nacmias B.

Neurodegener Dis Manag. 2014;4(1):73-81. doi: 10.2217/nmt.13.68.

Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents

Ambure P, Roy K.

Expert Opin Drug Discov. 2014 Jun;9(6):697-723. doi: 10.1517/17460441.2014.909404. Epub 2014 Apr 23.

Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments

Lista S, Zetterberg H, Dubois B, Blennow K, Hampel H.

J Neurol. 2014 Jun;261(6):1234-43. doi: 10.1007/s00415-014-7366-z. Epub 2014 May 8.

[Progress of dementia medicine: Special reference to Alzheimer's disease]

Utsumi K.

Hokkaido Igaku Zasshi. 2014 May;89(1):21-3.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17.

Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin

Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tüscher O, Fellgiebel A.

Neurology. 2014 Nov 18;83(21):1930-5. doi: 10.1212/WNL.0000000000001017. Epub 2014 Oct 24.

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR.

CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.

Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians

Asih PR, Chatterjee P, Verdile G, Gupta VB, Trengove RD, Martins RN.

Neurodegener Dis Manag. 2014;4(5):363-78. doi: 10.2217/nmt.14.29.

[Diagnosis and treatment of dementia: overview]

Furukawa K, Ishiki A, Tomita N, Arai H.

Rinsho Shinkeigaku. 2014;54(12):1171-3. doi: 10.5692/clinicalneurol.54.1171.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias